In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Aldeyra has resubmitted its new drug application for reproxalap, an investigational dry eye treatment, which contained new ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

The biotech industry faces a mix of longstanding and novel political challenges amid President Donald Trump’s second term.

For the second time, a person with DMD has died of acute liver failure after being treated with the one-time gene therapy Elevidys.

Solar stocks slid in off-hours trading after Senate Republicans kept in a full phase-out of solar and wind energy tax credits in [President Trump's budget bill]( ...